<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453567</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2018-04</org_study_id>
    <nct_id>NCT03453567</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice</brief_title>
  <acronym>IRIS AVR</acronym>
  <official_title>Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice; A Multicenter, Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated effectiveness and safety of aortic valve replacement in real-world
      clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause death</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>5 years</time_frame>
    <description>A. Death due to proximate cardiac cause B. Death caused by noncoronary vascular condition C. All procedure-related/surgery-related death D. All valve-related death E. Sudden or unwitnessed death F. Death of unknown cause
Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>5 years</time_frame>
    <description>Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All stroke and transient ischemic attack</measure>
    <time_frame>5 years</time_frame>
    <description>Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>5 years</time_frame>
    <description>Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access site complication</measure>
    <time_frame>5 years</time_frame>
    <description>Operation site complication Vascular access site and access-related complication
Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>5 years</time_frame>
    <description>Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent pacemaker insertion</measure>
    <time_frame>5 years</time_frame>
    <description>Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAVR-related complication</measure>
    <time_frame>5 years</time_frame>
    <description>A. Conversion to open surgery B. Coronary obstruction C. Mitral valve apparatus damage or dysfunction D. Cardiac tamponade E. Endocarditis F. Valve thrombosis G. Valve malpositioning H. TAV-in-TAV deployment
Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic valve dysfunction</measure>
    <time_frame>5 years</time_frame>
    <description>A. Prosthetic aortic valve stenosis B. Prosthesis-patient mismatch C. Prosthetic aortic valve regurgitation
Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event</measure>
    <time_frame>5 years</time_frame>
    <description>A. Device success B. Early safety (30 days)
Death, stroke, life-threatening bleeding, acute kidney injury, coronary stenosis requiring intervention, significant vascular complication, valve dysfunction requiring intervention C. Clinical efficacy (30 days)
Death, stroke, deteriorating heart failure or valve function requiring hospitalization, NYHA III or IV dyspnea, valve dysfunction
Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural valve deterioration</measure>
    <time_frame>5 years</time_frame>
    <description>Either Discharge or 30-day, at the earliest time point
1-,6-, and 12-months, and 3-,5-years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>New York Heart Association (NYHA) Functional Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of valve area</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Aortic valve area measured by echocardiography (mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset atrial fibrillation</measure>
    <time_frame>30 days and 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVR</arm_group_label>
    <description>Transcatheter Aortic Valve Replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sutureless AVR</arm_group_label>
    <description>Sutureless Aortic Valve Replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional AVR</arm_group_label>
    <description>Conventional Aortic Valve Replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Valve Replacement</intervention_name>
    <description>Aortic valve replacement</description>
    <arm_group_label>TAVR</arm_group_label>
    <arm_group_label>Sutureless AVR</arm_group_label>
    <arm_group_label>Conventional AVR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with aortic valve replacement
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 19 and more

          -  Patient with aortic valve replacement

        Exclusion Criteria:

          -  Combined with mitral stenosis requiring surgery or aorta stenosis

          -  Acute bacterial endocarditis within 1 month of valve replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suk-Jung Choo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-jung Park, MD</last_name>
    <email>sjpark@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-hee Ham, RN</last_name>
    <phone>82230104728</phone>
    <email>cvcrc5@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>Professor, Division of Cardiology</investigator_title>
  </responsible_party>
  <keyword>TAVR</keyword>
  <keyword>SAVR</keyword>
  <keyword>TAVI</keyword>
  <keyword>Conventional AVR</keyword>
  <keyword>Sutureless AVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

